Abbisko Cayman Limited (HK:2256) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Abbisko Cayman Limited’s subsidiary, Abbisko Therapeutics, revealed promising dose selection results for pimicotinib, a CSF-1R inhibitor aimed at treating Tenosynovial Giant Cell Tumour, at the ACoP 2024 conference. The study recommends a 50 mg daily dose for global treatment development, based on integrated pharmacokinetics, safety, and efficacy data. Investors are advised to exercise caution as the drug’s market success is not guaranteed.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.